Year: 2025

📢 Product Launch Announcement: Minoxymax 5 We are proud to introduce Minoxymax 5, an innovative oral solution containing Minoxidil 5 mg, developed to effectively address male and female pattern hair loss. Minoxymax 5 offers a scientifically proven, convenient, and powerful approach for doctors, hospitals, and patients seeking clinically effective hair regrowth solutions. 🔹 About Minoxymax…

📢 Product Launch Announcement: Minoxymax 2.5 We are proud to announce the launch of Minoxymax 2.5, a breakthrough in oral therapy for male and female pattern hair loss, offering patients and healthcare providers an effective and convenient alternative to traditional topical treatments. Minoxymax 2.5 brings together clinical innovation and trusted care, empowering doctors, hospitals, and…

📢 Product Launch Announcement: Iverclear 6 We are pleased to announce the launch of Iverclear 6, our advanced formulation of Ivermectin 6 mg, developed to offer effective, reliable, and convenient treatment for a broad range of worm infections and parasitic diseases. With a strong foundation in clinical research and global therapeutic experience, Iverclear 6 embodies…

📢 Product Launch Announcement: Hairpecia 1 We are proud to announce the launch of Hairpecia 1, a clinically trusted formulation of Finasteride 1 mg, specially developed to combat male pattern hair loss and restore self-confidence. Hairpecia 1 represents a significant advancement in the management of androgenetic alopecia, offering doctors, hospitals, and patients a highly effective,…

📢 Product Launch: Empasmile 10 We are proud to announce the launch of Empasmile 10, our innovative formulation of Empagliflozin 10 mg, designed to transform the management of type 2 diabetes mellitus. Built on a foundation of rigorous science, clinical excellence, and patient-focused innovation, Empasmile 10 provides healthcare professionals and patients with a reliable, advanced…

📢 Launch Announcement: Baracavir 0.5 We are proud to announce the launch of Baracavir 0.5, a high-quality formulation of Entecavir 0.5 mg, developed to set a new standard in the management of chronic Hepatitis B virus (HBV) infection. Backed by clinical research and manufactured to the highest standards of pharmaceutical excellence, Baracavir 0.5 represents our…

🌟 Launching AZIFAITH 500 We are proud to introduce Azifaith 500 — a next-generation antibiotic solution formulated with Azithromycin 500 mg, designed to deliver powerful and dependable treatment for pneumonia and related respiratory infections. Backed by scientific excellence and produced under the highest quality standards, Azifaith 500 offers doctors, hospitals, and patients a trusted choice…

Introducing Azifaith 250: Redefining the Standard in Pneumonia Treatment We are proud to announce the launch of Azifaith 250, a next-generation azithromycin formulation engineered to deliver fast, effective, and dependable treatment for pneumonia and other serious respiratory infections. Azifaith 250 belongs to the macrolide class of antibiotics, renowned for its broad-spectrum activity and exceptional tissue…

Introducing Tadalaforce 20: Empowering Confidence, Restoring Vitality We are proud to announce the launch of Tadalaforce 20, a cutting-edge tadalafil formulation designed to provide reliable, long-lasting support in the treatment of erectile dysfunction (ED).Tadalaforce 20 represents the perfect synergy of medical innovation and patient-centered care — offering men a renewed sense of confidence, intimacy, and…

Introducing Empasmile 25: Advancing the Future of Diabetes Care We are proud to announce the launch of Empasmile 25, an advanced empagliflozin-based therapy developed to transform the management of type 2 diabetes mellitus. With a proven track record in glycemic control and cardiovascular protection, Empasmile 25 empowers healthcare providers and patients to achieve better outcomes…